Berlin : Springer-Verlag ; : — Google Preview. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an week phase III clinical trial. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.
Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol. Genetic architecture of cancer and other complex diseases: lessons learned and future directions.
Sardana G , Diamandis EP. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomarkers Med.
Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis.
Clin Cancer Res. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. Raynaud JP. Testosterone deficiency syndrome: treatment and cancer risk. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone.
A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol Lausanne. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.
BMC Med. Lower plasma testosterone or dihydrotestosterone, but not estradiol, is associated with symptoms of intermittent claudication in older men. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Testosterone, dihydrotestosterone and estradiol are differentially associated with carotid intima-media thickness and the presence of carotid plaque in men with and without coronary artery disease.
Endocr J. Dihydrotestosterone treatment in men with coronary artery disease. Influence on sex hormones, lipid profile, insulin resistance and fibrinogen. Influence on myocardial ischemia and left ventricle. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study.
Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease. Am J Cardiol. Mol Hum Reprod. Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol.
Macrophage may responses to androgen via its receptor. Med Sci Monit. Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Circulating endothelial progenitor cells and cardiovascular outcomes. Circ Res. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway.
Androgen receptor in human endothelial cells. J Endocrinol. Am J Transl Res. Reduced number of circulating endothelial progenitor cells in hypogonadal men. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: a retrospective cohort study of the Veterans Administration database.
Glueck CJ , Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Effects in mice of testosterone and dihydrotestosterone on platelet aggregation in injured arterioles and ex vivo. Thromb Res. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Inhibition of oxidative-stress-induced platelet aggregation by androgen at physiological levels via its receptor is associated with the reduction of thromboxane A2 release from platelets.
Association of testosterone levels with anemia in older men. A controlled clinical trial. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.
Am J Physiol Endocrinol Metab. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone.
Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res. Association between polymorphisms in erythropoietin gene and upper limit haematocrit levels among regular blood donors. Transfus Clin Biol. Androgen-induced erythrocytosis: is it erythropoietin? Am J Hematol. Influence of exogenous oestrogen or anti- androgen administration on soluble transferrin receptor in human plasma. Claustres M , Sultan C. Androgen and erythropoiesis: evidence for an androgen receptor in erythroblasts from human bone marrow cultures.
Horm Res. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. The pharmacology and metabolism of testosterone undecanoate TU , a new orally active androgen. Acta Endocrinol Copenh. Steroidogenesis in the skin: implications for local immune functions. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab. Sexual hormones in human skin. Horm Metab Res. Deslypere JP , Vermeulen A.
Aging and tissue androgens. Influence of age on steroid concentrations in skin and striated muscle in women and in cardiac muscle and lung tissue in men. Percutaneous absorption of steroids. J Invest Dermatol. Int J Androl. J Drugs Dermatol. The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res. Effect of dihydrotestosterone on the upregulation of inflammatory cytokines in cultured sebocytes. Rahnayake D , Sinclair R.
Male androgenetic alopecia. Expert Opin on Pharmacother. Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Hum Genet. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.
Am J Hum Genet. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone.
Understanding androgen action in adipose tissue. Androgen metabolism in adipose tissue: recent advances. Androgens, body fat distribution and adipogenesis. Curr Obes Rep. Androgen treatment of abdominally obese men. Obes Res. Testosterone and regional fat distribution. Horm Mol Biol Clin Investig. Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women. Sato K , Iemitsu M. Exercise and sex steroid hormones in skeletal muscle.
Updated survey of the steroid-converting enzymes in human adipose tissues. Fat tissue: a steroid reservoir and site of steroid metabolism. Transcriptomic characterization of the long-term dihydrotestosterone effects in adipose tissue. Obesity Silver Spring.
Exogenous testosterone T alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Male sexual function can be maintained without aromatization: randomized placebo-controlled trial of dihydrotestosterone DHT in healthy, older men for 24 months. J Sex Med. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.
J Bone Miner Res. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes.
Diabetes Care. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents Abstract.
DHT in Women. Swerdloff , Ronald S. Oxford Academic. Robert E. Clarus Therapeutics, Inc. Stephanie T. Christina Wang. Wael A. Cite Cite Ronald S. Select Format Select format. Permissions Icon Permissions. Open in new tab Download slide. Table 1. Study Description and Population.
Duration Months. N Completed. Assay Method. Open in new tab. Table 2. Study Description. Length of Exposure. DHT Assay Method. Table 3. Form of ART. Observed Effects on Prostate. Table 4. Oral TU Dose. Androgen Assay Method. Google Scholar Crossref. Search ADS. Google Scholar PubMed. No impairment in brachial artery size or flow in response to glyceryl trinitrate—induced dilatation. Older men; mean age, 58 Healthy men older than 50 years with no known prostate disease Healthy men; age 35—55 Case report: Pr CA in hypogonadism Medical castration healthy men DHT Rx Learn more about the gene associated with 5-alpha reductase deficiency SRD5A2.
Inheritance This condition is inherited in an autosomal recessive pattern , which means both copies of the SRD5A2 gene in each cell have a mutation.
Other Names for This Condition Familial incomplete male pseudohermaphroditism, type 2 Male pseudohermaphroditism due to 5-alpha-reductase deficiency PPSH Pseudovaginal perineoscrotal hypospadias Steroid 5-alpha-reductase deficiency. Genetic and Rare Diseases Information Center 5-alpha reductase deficiency. A novel missense mutation of 5-alpha reductase type 2 gene SRD5A2 leads to severe male pseudohermaphroditism in a Turkish family.
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency. J Androl. Epub Jul 3. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav. New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2. J Mol Med Berl.
Epub Mar Ive been torrenting for months now with no problem, and two days ago something weird happened. Torrent said it encountered an error not a named one, a windows "program error needs to shut down send error report?
Yes I have the space, Yes I deleted a bunch of old stuff just to make sure, No I dont have other torrents running, No there hasnt been any changes in my computers main physiology over the past 2 days, Yes Ive used both start and force start on said torrents. So my question to you is, why?!?! Do you have any networking-related software on your computer that auto-updates After derivatization to picolinate ester forms, the concentrations of steroids were determined using LC-MS.
All experiment were performed thrice. Quantification of target gene expression in samples was accomplished by measuring the fractional cycle number at which the amount of expression reached a fixed threshold CT. Relative quantification was given by CT values, determined by triplicate reactions. The cell culture medium were changed every 3 days and cell numbers were counted every 3 days. For cell counts, trypan blue was used to measure cell viability. All analyses were performed using SPSS version How to cite this article : Ando, T.
Naito, S. Updated Japanese urological association guidelines on prostate-specific antigen-based screening for prostate cancer in CAS Google Scholar. Matsuda, T. Cancer incidence and incidence rates in Japan in based on data from 14 population-based cancer registries in the monitoring of cancer incidence in Japan MCIJ project.
PubMed Google Scholar. Huggins, C. Studies on prostatic cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. Oh, W. Management of hormone refractory prostate cancer: current standards and future prospects.
Page, S. Persistent intraprostatic androgen concentrations after medical castration in healthy men. Mohler, J. The androgen axis in recurrent prostate cancer. Titus, M. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Montgomery, R. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Nishiyama, T. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Geller, J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Labrie, F. Adrenal androgens and intracrinology. Bauman, D. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia and prostate cancer. Rizner, T. Human type 3 3alpha-hydroxysteroid dehydrogenase aldo-keto reductase 1C2 and androgen metabolism in prostate cells.
Shaw, G. Prostate formation in a marsupial is mediated by the testicular androgen 5 alpha-androstane-3 alpha,17 beta-diol. USA 97, — Weihua, Z. USA 98, — Horvath, L. Royuela, M. USA 99, — Guerini, V. Chang, K. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. USA , — Jacobi, G. Studies on the mechanism of 3 alpha-androstanediol-induced growth of the dog prostate.
Khanna, M. Substrate specificity, gene structure and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. Wilson, J.
0コメント